Company Profile
BMYBristol-Myers Squibb Company Stock Price, News & Analysis
- Ticker:
- BMY
- Exchange:
- NYSE
- Sector:
- Oncology, Immunotherapy
- Location:
- United States
Stock performance
62.56 USD (+0.76%)
Close
Last updated: July 27, 2026
111B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, BMY closed up 0.76% at $62.56. No new same-company headline was identified in the current news window.
Company overview
Business overview
Bristol Myers Squibb develops and commercializes medicines across oncology, hematology, immunology, and cardiovascular disease. Its market story is driven by cash flow durability, pipeline replacement, and lifecycle pressure across a large commercial base.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NYSE, BMY has a global commercial footprint. It sits in large-cap biopharmaceuticals with broad therapeutic exposure.
Business Model Characteristics
The company generates cash from mature products while using the pipeline and business development to offset patent and growth risk. Investors watch earnings, clinical data, and launch execution for signs of a successful transition.
Position Within the Biotechnology Landscape
BMY is a mature large-cap biopharma with biotech-like catalyst sensitivity around oncology and immunology programs. It is less volatile than clinical-stage names, but the market still reacts to pipeline and lifecycle signals.
Future catalysts
Bristol Myers Squibb’s most important catalyst window is iberdomide, with the FDA filing and PDUFA path in relapsed/refractory multiple myeloma, plus mezigdomide’s Phase 3 SUCCESSOR-2 readout. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BMYBristol-Myers Squibb Company (BMY)?
BMYBristol-Myers Squibb Company (BMY) most recently closed at 62.56 USD, a +0.76% move versus the previous session.
What is the market cap of BMYBristol-Myers Squibb Company (BMY)?
BMYBristol-Myers Squibb Company currently has a market capitalization of 111B USD on BioPharmSignal.
What does BMYBristol-Myers Squibb Company do?
Bristol Myers Squibb develops and commercializes medicines across oncology, hematology, immunology, and cardiovascular disease. Its market story is driven by cash flow durability, pipeline replacement, and lifecycle pressure across a large commercial base.
On which exchange is BMY stock listed?
BMYBristol-Myers Squibb Company (BMY) is associated with NYSE, United States, Oncology, Immunotherapy.
What is SUCCESSOR-2?
Bristol Myers Squibb’s most important catalyst window is iberdomide, with the FDA filing and PDUFA path in relapsed/refractory multiple myeloma, plus mezigdomide’s Phase 3 SUCCESSOR-2 readout.
Which conditions is BMYBristol-Myers Squibb Company targeting with SUCCESSOR-2?
BMYBristol-Myers Squibb Company is associated with oncology, immunology, cardiovascular disease based on its company overview and current catalyst commentary.
How does BMYBristol-Myers Squibb Company describe recent progress with SUCCESSOR-2?
Bristol Myers Squibb’s most important catalyst window is iberdomide, with the FDA filing and PDUFA path in relapsed/refractory multiple myeloma, plus mezigdomide’s Phase 3 SUCCESSOR-2 readout.
What is Bristol?
Bristol Myers Squibb develops and commercializes medicines across oncology, hematology, immunology, and cardiovascular disease.